Jump to content

TRP - TISSUE REPAIR LIMITED


nipper
 Share

Recommended Posts

Tissue Repair Ltd (TRP) is a clinical stage biopharmaceutical company developing advanced wound healing products targeting applications in the chronic wound and cosmetic procedure aftercare markets, with the potential for further development of related technologies.

Their core focus is part of the chronic wound market which, in the USA alone, is estimated to cost the federal healthcare system up to US$50bn (for both primary and secondary diagnosis, including the cost of infections and all costs associated with care including but not limited to hospital and medical costs). Tissue Repair is initially targeting the US$1.5bn market of active wound care products (biologics) used to treat these conditions in the USA. Tissue Repair is also targeting the market for aftercare of minimally invasive cosmetic procedures.

Tissue Repair is in the final stages of closing its Phase II program having completed Phase IIB clinical trial work and end of study statistical analysis in 2020 for its chronic wound product, TR-987. It is planning to commence pivotal Phase III trials for its chronic wound product in 2022, subject to FDA approval. Tissue Repair is also preparing to launch its cosmeceutical product (TR Pro+) in the Australian market in 2022, a postprocedure gel to be used following some minimally invasive cosmetic procedures.

Tissue Repair is in the process of undertaking the requisite planning, analytical identification and manufacturing work required to commence Phase III clinical trials for its chronic wound care product.
 

Listing date 18 November 2021 ; 11:00 AM AEDT ##
Company contact details https://tissuerepair.com.au/
Principal Activities Tissue Repair is a clinical stage biopharmaceutical company developing an advanced wound healing technology targeting applications in the chronic wound and cosmetic procedure markets.
   
Issue Price AUD 1.15
Issue Type Ordinary Fully Paid Shares
Security code TRP
Capital to be Raised $22,000,000
Expected offer close date 29 October 2021
Underwriter Not underwritten. Bell Potter Securities Limited and Morgans Corporate Limited (Joint lead managers)
Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share

×
×
  • Create New...